Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited Pierre Fabre to submit evidence for the clinical and cost-effectiveness of encorafenib with binimetinib (Enco + Bini) versus dabrafenib with trametinib (Dab + Tram) as a first-lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Houten, Rachel, Greenhalgh, Janette, Mahon, James, Nevitt, Sarah, Beale, Sophie, Boland, Angela, Lambe, Tosin, Dundar, Yenal, Kotas, Eleanor, McEntee, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895893/
https://www.ncbi.nlm.nih.gov/pubmed/32291725
http://dx.doi.org/10.1007/s41669-020-00206-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895893/
https://www.ncbi.nlm.nih.gov/pubmed/32291725
http://dx.doi.org/10.1007/s41669-020-00206-x

Ejemplares similares